Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouse

Farners Amargant i Riera,Carol Vieira,Michele Pritchard,Francesca Duncan

DOI: https://doi.org/10.1101/2024.06.21.600035

2024-06-25

Abstract:The female reproductive system is one of the first to age in humans, resulting in infertility and endocrine disruptions. The aging ovary assumes a fibro-inflammatory milieu which negatively impacts gamete quantity and quality as well as ovulation. Here we tested whether the systemic delivery of anti-inflammatory (Etanercept) or anti-fibrotic (Pirfenidone) drugs attenuates ovarian aging in mice. We first evaluated the ability of these drugs to decrease the expression of fibro-inflammatory genes in primary ovarian stromal cells. Whereas Etanercept did not block Tnf expression in ovarian stromal cells, Pirfenidone significantly reduced Col1a1 expression. We then tested Pirfenidone in vivo where the drug was delivered systemically via mini-osmotic pumps for 6-weeks. Pirfenidone mitigated the age-dependent increase in ovarian fibrosis without impacting overall health parameters. Ovarian function was improved in Pirfenidone-treated mice as evidenced by increased follicle and corpora lutea number, AMH levels, and improved estrous cyclicity. Transcriptomic analysis revealed that Pirfenidone treatment resulted in an upregulation of reproductive function-related genes at 8.5 months and a downregulation of inflammatory genes at 12 months of age. These findings demonstrate that reducing the fibroinflammatory ovarian microenvironment improves ovarian function, thereby supporting modulating the ovarian environment as a therapeutic avenue to extend reproductive longevity.

Developmental Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: whether systematic low - dose anti - fibrosis treatment can slow down ovarian aging in mice. Specifically, the researchers tested whether anti - inflammatory drugs (Etanercept) or anti - fibrosis drugs (Pirfenidone) can improve ovarian function by reducing the fibro - inflammatory response in the ovaries, thereby prolonging the reproductive lifespan.

### Research Background
As women age, the reproductive system is one of the first organs to show signs of aging, which leads to infertility and endocrine disorders. The aging ovary forms a fibro - inflammatory microenvironment, which has a negative impact on the quantity and quality of eggs and ovulation. Therefore, finding effective ways to delay ovarian aging and improve ovarian function is of great significance for prolonging women's reproductive lifespan.

### Research Methods
1. **In vitro experiments**: The researchers first evaluated the ability of these drugs to reduce fibro - inflammatory gene expression in primary ovarian stromal cells.
2. **In vivo experiments**: Then Pirfenidone was systematically administered via a mini - osmotic pump for 6 weeks to observe its effect on ovarian aging.
3. **Histological analysis**: The degree of ovarian fibrosis was evaluated by HE staining and Picrosirius Red staining.
4. **Functional indicators**: Changes in the number of follicles, the number of corpora lutea, AMH levels, and estrous cycles were detected.
5. **Transcriptome analysis**: Changes in ovarian gene expression after Pirfenidone treatment were analyzed by RNA sequencing.

### Main Findings
- **In vitro experiment results**: Pirfenidone significantly reduced the expression of Col1a1, while Etanercept failed to block the expression of Tnf.
- **In vivo experiment results**: Pirfenidone treatment significantly alleviated ovarian fibrosis but did not affect overall health parameters. The ovarian function of mice in the treatment group was improved, as manifested by an increase in the number of follicles and corpora lutea, an increase in AMH levels, and a more regular estrous cycle.
- **Transcriptome analysis**: After Pirfenidone treatment, genes related to reproductive function were up - regulated at 8.5 months, while inflammation - related genes were down - regulated at 12 months.

### Conclusion
This study shows that by reducing the fibro - inflammatory microenvironment in the ovaries, ovarian function can be improved, supporting the regulation of the ovarian environment as a therapeutic strategy for prolonging the reproductive lifespan. This finding provides important pre - clinical data support for the clinical application of anti - fibrosis drugs to improve ovarian function.